Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
High Dose Chemotherapy Prolongs Survival for Leukemia
Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E
Past Highlights
Results:
1 -10 of 18
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
Last Modified:
11/14/2008
 
First Published:
2/21/2003
1.
Phase I/II Study of Melanoma Vaccine Comprising Autologous Dendritic Cells Pulsed With Tumor Antigen Peptides With or Without Ex Vivo CD40- Ligand and Denileukin Diftitox in Patients With HLA-A1- and/or HLA-A2.1-Positive Stage III or IV Melanoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Active
over 18
Other
ERLANGEN-ONTAK
EU-20246, NCT00056134
Last Modified:
10/28/2008
 
First Published:
1/16/2007
2.
Phase I/II Study of Denileukin Diftitox in Patients With Refractory Advanced Breast Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Biomarker/Laboratory analysis, Treatment
Active
18 and over
NCI
UWCC-6308
UWCC-05-6951-A, NCT00425672
3.
Study of ONTAK in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
18 and over
Pharmaceutical / Industry
L4389-34
NCT00055146
Last Modified:
7/28/2006
 
First Published:
8/24/2005
4.
Phase II Study of Denileukin Diftitox in Patients With Tac-Expressing HTLV-1-Associated Adult T-Cell Leukemia/Lymphoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
18 and over
NCI
NCI-05-C-0185
NCI-P6591, NCT00138190
Last Modified:
7/17/2007
 
First Published:
10/7/2005
5.
Phase II Study of Denileukin Diftitox in Patients With Stage III or IV Ovarian Epithelial or Primary Peritoneal Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
18 and over
Other
TULCC-TC-01-4
TULCC-C0307, NCT00238186
6.
Phase II Trial of Ontak With Metastatic Melanoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
18 and over
Other
076.06
NCT00299689
7.
A Pilot Study to Determine the Safety of the Combination of Ontak in Combination With CHOP in Peripheral T-Cell Lymphoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
18 and over
Other
0507000369
NCT00337987
First Published:
4/6/2007
8.
Phase II Study of Rituximab and Denileukin Diftitox in Patients With Previously Untreated Stage III or IV Follicular B-Cell Non-Hodgkin's Lymphoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Biomarker/Laboratory analysis, Treatment
Active
18 and over
NCI
NCCTG-N0682
N0682, NCT00460109
9.
Vaccination Plus Ontak in Patients With Metastatic Melanoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
18 and over
Other
15232B
NCT00515528
10.
Treatment of Peripheral T-Cell Lymphoma With Aggressive Induction Chemotherapy Followed by Autologous Stem Cell Transplant Using Denileukin Diftitox (Ontak)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
18 to 70
Other
UC-PTCL-ONTAK
NCT00632827
Select All on One Page
1
2
Next >
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute